195 related articles for article (PubMed ID: 33340533)
1. Product-Specific Impact of Viscosity Modulating Formulation Excipients During Ultra-High Concentration Biotherapeutics Drug Product Development.
Rodrigues D; Tanenbaum LM; Thirumangalathu R; Somani S; Zhang K; Kumar V; Amin K; Thakkar SV
J Pharm Sci; 2021 Mar; 110(3):1077-1082. PubMed ID: 33340533
[TBL] [Abstract][Full Text] [Related]
2. Computational Characterization of Antibody-Excipient Interactions for Rational Excipient Selection Using the Site Identification by Ligand Competitive Saturation-Biologics Approach.
Jo S; Xu A; Curtis JE; Somani S; MacKerell AD
Mol Pharm; 2020 Nov; 17(11):4323-4333. PubMed ID: 32965126
[TBL] [Abstract][Full Text] [Related]
3. A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities.
Whitaker N; Xiong J; Pace SE; Kumar V; Middaugh CR; Joshi SB; Volkin DB
J Pharm Sci; 2017 Nov; 106(11):3230-3241. PubMed ID: 28668340
[TBL] [Abstract][Full Text] [Related]
4. Toward Biotherapeutics Formulation Composition Engineering using Site-Identification by Ligand Competitive Saturation (SILCS).
Somani S; Jo S; Thirumangalathu R; Rodrigues D; Tanenbaum LM; Amin K; MacKerell AD; Thakkar SV
J Pharm Sci; 2021 Mar; 110(3):1103-1110. PubMed ID: 33137372
[TBL] [Abstract][Full Text] [Related]
5. Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering.
Xu AY; Castellanos MM; Mattison K; Krueger S; Curtis JE
Mol Pharm; 2019 Oct; 16(10):4319-4338. PubMed ID: 31487466
[TBL] [Abstract][Full Text] [Related]
6. Caffeine as a Viscosity Reducer for Highly Concentrated Monoclonal Antibody Solutions.
Zeng Y; Tran T; Wuthrich P; Naik S; Davagnino J; Greene DG; Mahoney RP; Soane DS
J Pharm Sci; 2021 Nov; 110(11):3594-3604. PubMed ID: 34181992
[TBL] [Abstract][Full Text] [Related]
7. Viscosity Reduction and Stability Enhancement of Monoclonal Antibody Formulations Using Derivatives of Amino Acids.
Srivastava A; O'Dell C; Bolessa E; McLinden S; Fortin L; Deorkar N
J Pharm Sci; 2022 Oct; 111(10):2848-2856. PubMed ID: 35605688
[TBL] [Abstract][Full Text] [Related]
8. An Intercompany Perspective on Practical Experiences of Predicting, Optimizing and Analyzing High Concentration Biologic Therapeutic Formulations.
Desai PG; Garidel P; Gbormittah FO; Kamen DE; Mills BJ; Narasimhan CN; Singh S; Stokes ESE; Walsh ER
J Pharm Sci; 2023 Feb; 112(2):359-369. PubMed ID: 36442683
[TBL] [Abstract][Full Text] [Related]
9. Sterile Filtration of Highly Concentrated Protein Formulations: Impact of Protein Concentration, Formulation Composition, and Filter Material.
Allmendinger A; Mueller R; Huwyler J; Mahler HC; Fischer S
J Pharm Sci; 2015 Oct; 104(10):3319-29. PubMed ID: 26149748
[TBL] [Abstract][Full Text] [Related]
10. Technology development to evaluate the effectiveness of viscosity reducing excipients.
Banik N; Braun S; Gerit Brandenburg J; Fricker G; Kalonia DS; Rosenkranz T
Int J Pharm; 2022 Oct; 626():122204. PubMed ID: 36116691
[TBL] [Abstract][Full Text] [Related]
11. Machine Learning Models of Antibody-Excipient Preferential Interactions for Use in Computational Formulation Design.
Cloutier TK; Sudrik C; Mody N; Sathish HA; Trout BL
Mol Pharm; 2020 Sep; 17(9):3589-3599. PubMed ID: 32794710
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Excipient Effects on Reversible Self-Association, Backbone Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High Concentrations: Part 1.
Hu Y; Arora J; Joshi SB; Esfandiary R; Middaugh CR; Weis DD; Volkin DB
J Pharm Sci; 2020 Jan; 109(1):340-352. PubMed ID: 31201906
[TBL] [Abstract][Full Text] [Related]
13. Molecular computations of preferential interactions of proline, arginine.HCl, and NaCl with IgG1 antibodies and their impact on aggregation and viscosity.
Cloutier TK; Sudrik C; Mody N; Hasige SA; Trout BL
MAbs; 2020; 12(1):1816312. PubMed ID: 32938318
[TBL] [Abstract][Full Text] [Related]
14. Application of a High Throughput and Automated Workflow to Therapeutic Protein Formulation Development.
Ren CD; Qi W; Wyatt EA; Yeary J; Westland K; Berke M; Rathore N
J Pharm Sci; 2021 Mar; 110(3):1130-1141. PubMed ID: 33203511
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Electrostatic Mediated Antibody Liquid-Liquid Phase Separation by Charged and Noncharged Preferentially Excluded Excipients.
Banks DD; Cordia JF
Mol Pharm; 2021 Mar; 18(3):1285-1292. PubMed ID: 33555888
[TBL] [Abstract][Full Text] [Related]
16. Molecular Computations of Preferential Interaction Coefficients of IgG1 Monoclonal Antibodies with Sorbitol, Sucrose, and Trehalose and the Impact of These Excipients on Aggregation and Viscosity.
Cloutier T; Sudrik C; Mody N; Sathish HA; Trout BL
Mol Pharm; 2019 Aug; 16(8):3657-3664. PubMed ID: 31276620
[TBL] [Abstract][Full Text] [Related]
17. Biopharmaceutical formulations for pre-filled delivery devices.
Jezek J; Darton NJ; Derham BK; Royle N; Simpson I
Expert Opin Drug Deliv; 2013 Jun; 10(6):811-28. PubMed ID: 23506207
[TBL] [Abstract][Full Text] [Related]
18. Novel salts of dipicolinic acid as viscosity modifiers for high concentration antibody solutions.
Ke P; Batalha IL; Dobson A; Tejeda-Montes E; Ekizoglou S; Christie G; McCabe J; van der Walle CF
Int J Pharm; 2018 Sep; 548(1):682-688. PubMed ID: 30009985
[TBL] [Abstract][Full Text] [Related]
19. NMR spectroscopy as a characterization tool enabling biologics formulation development.
Ma J; Pathirana C; Liu DQ; Miller SA
J Pharm Biomed Anal; 2023 Jan; 223():115110. PubMed ID: 36308923
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations.
Ghosh I; Gutka H; Krause ME; Clemens R; Kashi RS
MAbs; 2023; 15(1):2205540. PubMed ID: 37243580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
